| Company Name: |
Riedel-de Haen AG
|
| Tel: |
800 558-9160 |
| Email: |
|
| Products Intro: |
Purity:clone ct-21
|
|
| | MONOCLONALANTIBODIES Basic information |
| | MONOCLONALANTIBODIES Chemical Properties |
| | MONOCLONALANTIBODIES Usage And Synthesis |
| Description | Monoclonal antibodies (mAbs) are
powerful tools for tracking microorganisms because they
can recognize epitopes on the surface of bacteria and thus
serve as in situ identifiers. A series ofmAbs were produced
against whole cells of Pseudomonas putida KT2440 (84).
One was shown to recognize the O-antigen of P. putida
LPS. In the laboratory, this mAb specifically recognized
the strain when grown in different culture media and
at different growth stages. | | Uses | The mAb was used to track
the strain after its release in a mesocosm established in
Plussee Lake in northern Germany (85). | | General Description | A monoclonal antibody target for the treatment of osteoporosisis the RANKL, which is the essential mediator of osteoclasts.As pointed out in the osteoporosis discussion, theloss of calcium by increased osteoclastic activity and decreasedosteoclast apoptosis is opposed by a RANKLinhibitor, osteoprotegerin a 401-amino acid glycoprotein,and a member of the TNF superfamily. Rather than developa pharmaceutically acceptable osteoprotegerin, a fullyhuman monoclonal antibody, denosumab, that binds to theRANKL preventing its binding to RANK is being evaluatedfor the treatment of osteoporosis. The reported result is inhibitionof all stages of osteoclast activity. It is important tokeep a perspective when administering drugs that interferewith the immune system over long periods of time. RANKLis part of the normal bone remodeling process as well aswith pathological bone loss. The key is balance, and thiswill require long-term studies in patients with postmenopausalosteoporosis. |
| | MONOCLONALANTIBODIES Preparation Products And Raw materials |
|